[PDF][PDF] Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

P Laurent-Puig, A Cayre, G Manceau… - Journal of clinical …, 2009 - researchgate.net
P Laurent-Puig, A Cayre, G Manceau, E Buc, JB Bachet, T Lecomte, P Rougier, A Lievre…
Journal of clinical oncology, 2009researchgate.net
Purpose The occurrence of KRAS mutation is predictive of nonresponse and shorter survival
in patients treated by anti–epidermal growth factor receptor (anti-EGFR) antibody for
metastatic colorectal cancer (mCRC), leading the European Medicine Agency to limit its use
to patients with wild-type KRAS tumors. However, only half of these patients will benefit from
treatment, suggesting the need to identify additional biomarkers for cetuximab-based
treatment efficacy.
Purpose
The occurrence of KRAS mutation is predictive of nonresponse and shorter survival in patients treated by anti–epidermal growth factor receptor (anti-EGFR) antibody for metastatic colorectal cancer (mCRC), leading the European Medicine Agency to limit its use to patients with wild-type KRAS tumors. However, only half of these patients will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy.
researchgate.net